Therefore, in the present study, we evaluated the RAS, BRAF, and EGFR mutational status of tissue specimens representing normal skin, benign nevi, and cutaneous melanomas to determine the genetic landscape of pre-malignant and malignant stages of melanoma development and to investigate the extent to which these mutational signatures overlap. This evidence concerns the gene EGFR and melanoma.